Sector News

BioMarin snaps up Prosensa for around $840m

November 24, 2014
Life sciences
BioMarin Pharmaceuticals is acquiring Dutch group Prosensa in a deal valued at up to around $840 million.
 
The group said it will offer to buy all of Prosensa’s outstanding ordinary stock for $17.75 per share, for a total upfront consideration of around $680 million, as well as two $80-million milestones contingent on the approval of drisapersen for Duchenne Muscular Dystrophy (DMD) in the US (no later than May 15, 2016) and Europe (before February 15, 2017).
 
The move buys BioMarin access to multiple orphan-drug candidates – such as drisapersen, which has a shot at becoming first approved treatment for the rare genetic disease, albeit for about just 13% of patients (who carry a particular mutation) – leveraging the firm’s proprietary RNA-modulating technology platform for the treatment of various genotypes of DMD and other genetic disorders.      
 
The transaction is expected to be accounted for as a business combination, BioMarin said, also noting that it plans to maintain operations at Prosensa’s headquarters, based in Leiden, The Netherlands and integrate personnel from that office. 
 
“BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs,” said its chief Jean-Jacques Bienaimé, while Prosensa’s head said the move while help his firm’s mission by “bringing innovative therapies to patients across the world as quickly and efficiently as possible”.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).